Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story

Two randomized controlled clinical trials have evaluated the utility of posaconazole in antifungal prophylaxis in high-risk hematology patients.[1][1],[2][2] Posaconazole use was associated with a significant reduction in fungal infections and death due to invasive fungal disease in patients

[1]  T. C. White,et al.  Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis. , 2013, The Journal of infectious diseases.

[2]  L. Pagano,et al.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3) , 2013, Haematologica.

[3]  D. Andes,et al.  Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis , 2012, Antimicrobial Agents and Chemotherapy.

[4]  R. Foà,et al.  Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience , 2012, Haematologica.

[5]  L. Pagano,et al.  Update on invasive fungal disease. , 2011, Future microbiology.

[6]  R. Robitaille,et al.  Concentration of Antifungal Agents within Host Cell Membranes: a New Paradigm Governing the Efficacy of Prophylaxis , 2011, Antimicrobial Agents and Chemotherapy.

[7]  D. Kontoyiannis,et al.  How I treat mucormycosis. , 2011, Blood.

[8]  A. Thiébaut,et al.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.

[9]  O. Cars,et al.  Posaconazole in Human Serum: a Greater Pharmacodynamic Effect than Predicted by the Non-Protein-Bound Serum Concentration , 2011, Antimicrobial Agents and Chemotherapy.

[10]  M. Hallek,et al.  Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. , 2010, The Journal of antimicrobial chemotherapy.

[11]  J. Gobburu,et al.  Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma , 2010, Clinical pharmacology and therapeutics.

[12]  F. Farowski,et al.  Intracellular Concentrations of Posaconazole in Different Compartments of Peripheral Blood , 2010, Antimicrobial Agents and Chemotherapy.

[13]  J. Golden,et al.  Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects , 2008, Antimicrobial Agents and Chemotherapy.

[14]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[16]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[17]  S. Filler,et al.  Fungal Invasion of Normally Non-Phagocytic Host Cells , 2006, PLoS pathogens.

[18]  D. Loebenberg,et al.  In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts , 2006, Antimicrobial Agents and Chemotherapy.

[19]  D. Loebenberg,et al.  Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis , 2004, Antimicrobial Agents and Chemotherapy.

[20]  M. Moore,et al.  Uptake of Aspergillus fumigatus Conidia by Phagocytic and Nonphagocytic Cells In Vitro: Quantitation Using Strains Expressing Green Fluorescent Protein , 2002, Infection and Immunity.

[21]  Y. Asano-Mori,et al.  Diagnosis and Treatment of Mucormycosis in Patients with Hematological Malignancies. , 2016, Medical mycology journal.